Envestnet Asset Management Inc. Decreases Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Envestnet Asset Management Inc. cut its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 5.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,921,762 shares of the company's stock after selling 116,779 shares during the quarter. Envestnet Asset Management Inc. owned 0.17% of Teva Pharmaceutical Industries worth $29,537,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at $29,000. Golden State Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the first quarter worth $39,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $44,000. Compagnie Lombard Odier SCmA bought a new position in Teva Pharmaceutical Industries in the first quarter valued at about $54,000. Finally, Versant Capital Management Inc lifted its holdings in Teva Pharmaceutical Industries by 437.8% in the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock valued at $81,000 after acquiring an additional 4,312 shares during the period. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TEVA has been the subject of several research reports. Bank of America upped their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. UBS Group dropped their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective for the company. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a research report on Monday, April 28th. Finally, The Goldman Sachs Group assumed coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price target for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Price Performance

TEVA stock traded down $0.38 during trading on Tuesday, reaching $16.04. The company's stock had a trading volume of 12,003,298 shares, compared to its average volume of 10,282,509. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. The company's fifty day moving average is $17.09 and its 200-day moving average is $17.12. The company has a market capitalization of $18.40 billion, a P/E ratio of -13.95, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The firm had revenue of $3.89 billion during the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter last year, the business posted $0.48 earnings per share. The firm's revenue was up 1.9% on a year-over-year basis. On average, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the transaction, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.